Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy

Radiotherapy and Oncology

Volumn 63, Issue 3, 2002, Pages 285-291

  Bussink, Johan ^a   Stratford, Michael R L ^b   Van Der Kogel, Albert J ^a   Folkes, Lisa K ^b   Kaanders, Johannes H A M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Domperidone; Nicotinamide; Pharmacokinetics; Radiotherapy; Toxicity

Indexed keywords

DOMPERIDONE; NICOTINAMIDE; CARBOGEN; CARBON DIOXIDE; OXYGEN; RADIOSENSITIZING AGENT;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BLOOD LEVEL; ERYTHEMA; FEMALE; FLUSHING; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HYPOPHARYNX CARCINOMA; KIDNEY DISEASE; LARYNX CARCINOMA; MALE; MOUTH CARCINOMA; NAUSEA; OROPHARYNX CARCINOMA; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT OUTCOME; VERTIGO; VOMITING; BLOOD; CARCINOMA; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; OROPHARYNX TUMOR; RADIATION DOSE FRACTIONATION;

ADULT; AGED; AGED, 80 AND OVER; CARBON DIOXIDE; CARCINOMA; COMPARATIVE STUDY; DOMPERIDONE; DOSE FRACTIONATION; FEMALE; HUMAN; MALE; MIDDLE AGE; NAUSEA; NIACINAMIDE; OROPHARYNGEAL NEOPLASMS; OXYGEN; RADIATION-SENSITIZING AGENTS; VOMITING; HUMANS; MIDDLE AGED;

EID: 0036023445     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(02)00072-5     Document Type: Article

References (30)

1. Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: The experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer
2. Effects of the interaction between carbogen and nicotinamide on R3230 Ac tumor blood flow in Fischer 344 rats
3. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
4. The effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumour
5. Nicotinamide, Fluosol DA and carbogen: A strategy to reoxygenate acutely and chronically hypoxic cells in vivo
6. Nicotinamide pharmacokinetics in patients
7. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy
8. 2 predicts survival in advanced cancer of the uterine cervix
9. Tumor hypoxia in pelvic recurrences of cervical cancer
10. Tumor radiosensitization by nicotinamide: A result of improved blood perfusion and oxygenation
11. Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumour cells
12. Overcoming tumor radiation resistance resulting from acute hypoxia
13. Nicotinamide pharmacokinetics in humans and mice: A comparative assessment and the implications for radiotherapy
14. Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing
15. Optimising the administration of nicotinamide in patients that experience toxicity: In vivo studies with or without carbogen
16. Administration of nicotinamide during CHART: Pharmacokinetics, dose escalation, and clinical toxicity
17. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide
18. Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: Feasibility and toxicity
19. Administration of nicotinamide during a five- to seven-week course of radiotherapy: Pharmacokinetics, tolerance, and compliance
20. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer
21. ARCON: Experience in 215 patients with advanced head and neck cancer
22. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments
23. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
24. Domperidone, a novel and safe gastrokinetic anti-nauseant for the treatment of dyspepsia and vomiting
25. Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: Clinical considerations
26. Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy
27. The effect of nicotinamide on spontaneous and induced activity in smooth and skeletal muscle
28. High-performance liquid chromatographic determination of nicotinamide and its metabolites in human and murine plasma and urine
29. Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers
30. Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy